
According to the Institute of Safe Medication Practices, in 2011 there were more deaths connected to Pradaxa than any of the 800 other drugs on the market, and over a two-year period it was linked to 500 deaths in the U.S. alone. In July of 2012 the Pradaxa label was updated in the United Kingdom to state that it should not be given to patients with an increased risk of bleeding. The FDA determined that the drug should not be used in patients with mechanical heart valves. Patients older than 75 and those with kidney problems are also at risk, according to Boehringer’s own website.
Much of the risk is due to the absence of an “antidote” to Pradaxa. Vitamin K acts as an antidote to many blood thinners because it counteracts the thinning effect. It does not, however, work that way with Pradaxa, so there is little that can be done to save a Pradaxa patient who suffers excessive bleeding. According to statements made by Boehringer Ingelheim, the company assumed that Vitamin K would work for Pradaxa patients, too, so there is currently no antidote for excess bleeding from the drug.

